26095-59-0,MFCD00211142
Catalog No.:AA002RKD

26095-59-0 | Otilonium bromide

Pack Size
Purity
Availability
Price(USD)
Quantity
  
10mg
98%
in stock  
$6.00   $4.00
- +
50mg
98%
in stock  
$7.00   $5.00
- +
1g
98%
in stock  
$27.00   $19.00
- +
5g
98%
in stock  
$34.00   $24.00
- +
25g
98%
in stock  
$100.00   $70.00
- +
100g
98%
in stock  
$361.00 $253.00
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA002RKD
Chemical Name:
Otilonium bromide
CAS Number:
26095-59-0
Molecular Formula:
C29H43BrN2O4
Molecular Weight:
563.5667
MDL Number:
MFCD00211142
SMILES:
CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](CC)(CC)C.[Br-]
Properties
Computed Properties
 
Complexity:
600  
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
36  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0  
Rotatable Bond Count:
17  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  

Downstream Synthesis Route

[1]CurrentPatentAssignee:THEUNIVERSITYOFTEXASSYSTEM-WO2020/163479,2020,A1

[2]CurrentPatentAssignee:SIPINGOUKAITECH-CN115677525,2023,A

[1]CurrentPatentAssignee:THEUNIVERSITYOFTEXASSYSTEM-WO2020/163479,2020,A1

[2]CurrentPatentAssignee:SIPINGOUKAITECH-CN115677525,2023,A

[1]CurrentPatentAssignee:THEUNIVERSITYOFTEXASSYSTEM-WO2020/163479,2020,A1

[1]CurrentPatentAssignee:THEUNIVERSITYOFTEXASSYSTEM-WO2020/163479,2020,A1

Literature

Title: The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide.

Journal: European review for medical and pharmacological sciences 20120101

Title: Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.

Journal: Alimentary pharmacology & therapeutics 20110801

Title: Effect of otilonium bromide and ibodutant on the internalization of the NK2 receptor in human colon.

Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20110101

Title: Determination of the unstable drug otilonium bromide in human plasma by LC-ESI-MS and its application to a pharmacokinetic study.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101015

Title: Effect of otilonium bromide on contractile patterns in the human sigmoid colon.

Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20100601

Title: T-type Ca(2+) channel modulation by otilonium bromide.

Journal: American journal of physiology. Gastrointestinal and liver physiology 20100501

Title: Increased paracellular absorption by bile salts and P-glycoprotein stimulated efflux of otilonium bromide in Caco-2 cells monolayers as a model of intestinal barrier.

Journal: Journal of pharmaceutical sciences 20080901

Title: Oral bioavailability and enterohepatic recirculation of otilonium bromide in rats.

Journal: Archives of pharmacal research 20080101

Title: Irritable bowel syndrome.

Journal: Clinical drug investigation 20070101

Title: Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle.

Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20040401

Title: Otilonium bromide inhibits muscle contractions via L-type calcium channels in the rat colon.

Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20040401

Title: [New approaches to diagnosing and treating hyperkinetic biliary dyskinesia associated with chronic acalculous cholecystitis].

Journal: Klinicheskaia meditsina 20040101

Title: Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome.

Journal: Current pharmaceutical design 20040101

Title: The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts.

Journal: British journal of pharmacology 20021201

Title: Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome.

Journal: European journal of gastroenterology & hepatology 20021201

Title: Oesophageal motility disorders.

Journal: Lancet (London, England) 20020112

Title: Multicenter phase III clinical trial of otilonium bromide in irritable bowel syndrome.

Journal: Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20020101

Title: Optimisation and validation of a capillary electrophoresis method for the simultaneous determination of diazepam and otilonium bromide.

Journal: The Analyst 20011001

Title: [Functional intestinal disorders and quality of life].

Journal: Gastroenterologie clinique et biologique 20010901

Title: Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome.

Journal: Journal of physiology, Paris 20010101

Title: Effects exerted by otilonium bromide administration on precipitated opioid withdrawal syndrome in rats.

Journal: Toxicology 19970926

Title: Battaglia, G., et al., Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther, 1998. 12(10): p. 1003-10.

Title: Clave, P., et al., Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther, 2011. 34(4): p. 432-42.

Title: Lindqvist, S., et al., The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts. Br J Pharmacol, 2002. 137(7): p. 1134-42.

Title: Gandia, L., et al., Otilonium: a potent blocker of neuronal nicotinic ACh receptors in bovine chromaffin cells. Br J Pharmacol, 1996. 117(3): p. 463-470.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 26095-59-0
Tags:26095-59-0 Molecular Formula|26095-59-0 MDL|26095-59-0 SMILES|26095-59-0 Otilonium bromide
Catalog No.: AA002RKD
26095-59-0,MFCD00211142
26095-59-0 | Otilonium bromide
Pack Size: 10mg
Purity: 98%
in stock
$6.00 $4.00
Pack Size: 50mg
Purity: 98%
in stock
$7.00 $5.00
Pack Size: 1g
Purity: 98%
in stock
$27.00 $19.00
Pack Size: 5g
Purity: 98%
in stock
$34.00 $24.00
Pack Size: 25g
Purity: 98%
in stock
$100.00 $70.00
Pack Size: 100g
Purity: 98%
in stock
$361.00 $253.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA002RKD
Chemical Name: Otilonium bromide
CAS Number: 26095-59-0
Molecular Formula: C29H43BrN2O4
Molecular Weight: 563.5667
MDL Number: MFCD00211142
SMILES: CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](CC)(CC)C.[Br-]
Properties
Complexity: 600  
Covalently-Bonded Unit Count: 2  
Defined Atom Stereocenter Count: 0  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 36  
Hydrogen Bond Acceptor Count: 5  
Hydrogen Bond Donor Count: 1  
Isotope Atom Count: 0  
Rotatable Bond Count: 17  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
Downstream Synthesis Route
119-36-8    26095-59-0 

[1]CurrentPatentAssignee:THEUNIVERSITYOFTEXASSYSTEM-WO2020/163479,2020,A1

[2]CurrentPatentAssignee:SIPINGOUKAITECH-CN115677525,2023,A

111-83-1    26095-59-0 

[1]CurrentPatentAssignee:THEUNIVERSITYOFTEXASSYSTEM-WO2020/163479,2020,A1

[2]CurrentPatentAssignee:SIPINGOUKAITECH-CN115677525,2023,A

100-37-8    26095-59-0 

[1]CurrentPatentAssignee:THEUNIVERSITYOFTEXASSYSTEM-WO2020/163479,2020,A1

122-04-3    26095-59-0 

[1]CurrentPatentAssignee:THEUNIVERSITYOFTEXASSYSTEM-WO2020/163479,2020,A1

Literature fold

Title: The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide.

Journal: European review for medical and pharmacological sciences20120101

Title: Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.

Journal: Alimentary pharmacology & therapeutics20110801

Title: Effect of otilonium bromide and ibodutant on the internalization of the NK2 receptor in human colon.

Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society20110101

Title: Determination of the unstable drug otilonium bromide in human plasma by LC-ESI-MS and its application to a pharmacokinetic study.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences20101015

Title: Effect of otilonium bromide on contractile patterns in the human sigmoid colon.

Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society20100601

Title: T-type Ca(2+) channel modulation by otilonium bromide.

Journal: American journal of physiology. Gastrointestinal and liver physiology20100501

Title: Increased paracellular absorption by bile salts and P-glycoprotein stimulated efflux of otilonium bromide in Caco-2 cells monolayers as a model of intestinal barrier.

Journal: Journal of pharmaceutical sciences20080901

Title: Oral bioavailability and enterohepatic recirculation of otilonium bromide in rats.

Journal: Archives of pharmacal research20080101

Title: Irritable bowel syndrome.

Journal: Clinical drug investigation20070101

Title: Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle.

Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society20040401

Title: Otilonium bromide inhibits muscle contractions via L-type calcium channels in the rat colon.

Journal: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society20040401

Title: [New approaches to diagnosing and treating hyperkinetic biliary dyskinesia associated with chronic acalculous cholecystitis].

Journal: Klinicheskaia meditsina20040101

Title: Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome.

Journal: Current pharmaceutical design20040101

Title: The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts.

Journal: British journal of pharmacology20021201

Title: Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome.

Journal: European journal of gastroenterology & hepatology20021201

Title: Oesophageal motility disorders.

Journal: Lancet (London, England)20020112

Title: Multicenter phase III clinical trial of otilonium bromide in irritable bowel syndrome.

Journal: Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology20020101

Title: Optimisation and validation of a capillary electrophoresis method for the simultaneous determination of diazepam and otilonium bromide.

Journal: The Analyst20011001

Title: [Functional intestinal disorders and quality of life].

Journal: Gastroenterologie clinique et biologique20010901

Title: Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome.

Journal: Journal of physiology, Paris20010101

Title: Effects exerted by otilonium bromide administration on precipitated opioid withdrawal syndrome in rats.

Journal: Toxicology19970926

Title: Battaglia, G., et al., Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther, 1998. 12(10): p. 1003-10.

Title: Clave, P., et al., Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther, 2011. 34(4): p. 432-42.

Title: Lindqvist, S., et al., The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts. Br J Pharmacol, 2002. 137(7): p. 1134-42.

Title: Gandia, L., et al., Otilonium: a potent blocker of neuronal nicotinic ACh receptors in bovine chromaffin cells. Br J Pharmacol, 1996. 117(3): p. 463-470.

Building Blocks More >
2616-72-0
2616-72-0
3-((4-Chloro-2-methylphenyl)carbamoyl)naphthalen-2-yl dihydrogen phosphate
AA002RUK | MFCD00042716
261763-31-9
261763-31-9
Ethanone, 1-(2,6-difluoro-3-methylphenyl)-
AA002RZR | MFCD01631339
26197-93-3
26197-93-3
4-Bromothiobenzamide
AA002S5O | MFCD04114360
2627-77-2
2627-77-2
4'-Bromosalicylanilide
AA002SGL | MFCD00059615
26340-49-8
26340-49-8
2-Iodo-1h-indole
AA002SRF | MFCD10699391
26453-01-0
26453-01-0
2,3-Dihydro-1h-indene-2-carbonitrile
AA002T7B | MFCD12067446
26522-85-0
26522-85-0
Sodium malonate hydrate
AA002TGO | MFCD00149114
2750-44-9
2750-44-9
Trisiloxane, 3,3-dichloro-1,1,1,5,5,5-hexamethyl-
AA002TVG | MFCD01861694
27645-60-9
27645-60-9
4-[(4-Methoxyphenyl)carbonyl]benzonitrile
AA002U93 | MFCD01311594
2777-65-3
2777-65-3
10-Undecynoic acid
AA002UMT | MFCD00014389
Submit
© 2017 AA BLOCKS, INC. All rights reserved.